Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04697628 · OUTCOME

EQ-5D Visual Analog Scale (VAS) Scores

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer · Source last updated 2026-02-24

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
From start of treatment until end of follow-up

What was measured

EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state) ; higher scores indicate a better health state.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
anticipated Posting Date
2027-02
denom Units Selected
Participants
description
EQ5D is a participant rated questionnaire to assess health-related QoL in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state) ; higher scores indicate a better health state.
reporting Status
NOT_POSTED
time Frame
From start of treatment until end of follow-up
title
EQ-5D Visual Analog Scale (VAS) Scores
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice